On Jan. 28, the Food and Drug Administration (FDA) approved:

• Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients. Read more.
• Halaven (eribulin mesylate) for the treatment of liposarcoma that is unresectable or metastatic. Treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug. Read more.